Brouya schreef op 22 april 2018 11:40:
www.nashbiotechs.com/nash-biotech-ana...Well, being the first on the market with a drug considered by specialists as a future first line treatment, ELAFIBRANOR will be on a virgin market segment without any competition, the other drugs in the group heading the race are targeting subsets of patients or a very small but lucrative segment of advanced fibrosis or cirrhosis.
This would make it the first-line drug available that would be supplemented by other drugs depending on the progress of the disease.
That would make almost $ 3 billion in sales in 2025, just for the United States. You can go check the interactive projections on the corresponding page of the site.